Breast Cancer Screening Decision Aid

Status: Recruiting
Location: See location...
Intervention Type: Behavioral, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a survey-based study using an online panel. The goal of the study is to understand whether information about overdiagnosis influences breast cancer screening intention among older women. Participants are first asked a series of questions about breast cancer screening including their intention to continue screening, knowledge of screening, and beliefs about screening. They are then shown one of three videos about breast cancer screening that contain information about overdiagnosis or a fourth control video that is identical but contains no information about overdiagnosis. Participants are then again asked about screening intention, along with knowledge of screening, overdiagnosis, and questions around trust.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 70
Healthy Volunteers: t
View:

• 70 and older

• Able to participate in an English-language web-based survey

Locations
United States
Connecticut
Yale School of Medicine
RECRUITING
New Haven
Contact Information
Primary
Ilana Richman, MD
ilana.richman@yale.edu
203 737 1024
Time Frame
Start Date: 2025-07-23
Estimated Completion Date: 2025-08
Participants
Target number of participants: 300
Treatments
Experimental: Low risk of overdiagnosis
Participants in this arm will be shown a decision aid in which risk of overdiagnosis is low.
Experimental: Moderate risk of overdiagnosis
Participants in this arm will be shown a decision aid in which risk of overdiagnosis is moderate.
Experimental: High risk of overdiagnosis
Participants in this arm will be shown a decision aid in which risk of overdiagnosis is high.
Active_comparator: Control
Participants in this arm will be shown a video about breast cancer screening that is identical in all ways but contains no information about overdiagnosis.
Related Therapeutic Areas
Sponsors
Leads: Yale University
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov